Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
- Conditions
- COVID 19Juvenile Idiopathic ArthritisTreatment
- Registration Number
- NCT04407923
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Juvenile Idiopathic Arthritis is concerns by these fears (the patient and their parents). Patients are treated by several classes of immunomodulatory drugs, including non-steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs. The present study will characterize this issue by defining the proportion of patients whose usual treatment of Juvenile Idiopathic Arthritis has been modified in relation to the actual sanitary crisis, and also to return to school.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
- Juvenile Idiopathic Arthritis satisfying Edmonton criteria
- Ongoing DMARD therapy or AINS for 3 months
- Inhability to consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis 1 Day Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
CH de Belfort
🇫🇷Belfort, France
CHU de Bordeaux
🇫🇷Bordeaux, France
CHRU de Brest
🇫🇷Brest, France
AP-HP Hôpital Kremlin-Bicêtre
🇫🇷Le Kremlin-Bicêtre, France
CHU de Poitiers
🇫🇷Poitiers, France
CHU de Rennes
🇫🇷Rennes, France
CHU de Strasbourg
🇫🇷Strasbourg, France
CHU de Nancy
🇫🇷Vandœuvre les Nancy, France